Own the name of the medicine.
Digital Generics owns a unique portfolio of premium exact-match .com domain names for established generic medicines — strategic digital assets for pharmaceutical companies, healthcare organizations and ambitious healthcare projects.
The generic name is already known. The .com makes it ownable.
A pharmaceutical company cannot own an international nonproprietary name. But it can own one of the most important digital destinations associated with it.
Category ownership
An exact-match generic drug domain creates a distinct digital position around a molecule or therapeutic product category.
Memorable destination
Drug names are already used by physicians, pharmacists, patients and researchers. The corresponding .com is simple to communicate and remember.
Patient education
Build a focused information resource around a medicine, its approved uses, relevant educational materials and healthcare information.
Product strategy
Use the domain for a dedicated product initiative, corporate resource, campaign or relevant product experience.
Brand protection
Strategic ownership prevents an important digital asset associated with a key molecule from being controlled by another organization.
Long-term optionality
Redirect it today, develop it tomorrow or hold it as a strategic asset for future portfolio and market initiatives.
Teva acquired Olanzapine.com — then turned it into a significant search asset.
Teva Pharmaceuticals acquired the exact-match Olanzapine.com domain in November 2024 and began developing the website in 2025.
By 2026, the previously undeveloped pharmaceutical domain had built substantial organic visibility around a medicine represented directly within Teva’s generics portfolio.
Teva is one of the world’s major generic pharmaceutical companies. Olanzapine is represented within its pharmaceutical portfolio. Olanzapine.com is the exact digital address corresponding to that medicine.
The domain itself does not automatically create search rankings. Content quality, technical implementation, authority and competition all matter. What the Teva example demonstrates is how a highly relevant pharmaceutical domain can become valuable digital infrastructure when it is put to work by the right company.
From an undeveloped domain to a substantial pharmaceutical search asset in less than two years.
Teva acquired Olanzapine.com in late 2024, started development in 2025, and by 2026 the developed property had generated hundreds of thousands of search impressions and established a broad organic search footprint.
Approximate search figures based on supplied SEO/performance data as of September 2026. Search visibility fluctuates over time.
Find the domain that matches your pharmaceutical portfolio.
A straightforward path to strategic digital ownership.
Identify the right asset
Search the portfolio for generic-drug names relevant to your commercial portfolio, pipeline or strategic priorities.
Discuss the acquisition
Contact Digital Generics directly to discuss the domain, acquisition terms and transfer process.
Put the domain to work
Redirect it, build a dedicated resource or incorporate it into a longer-term pharmaceutical digital strategy.
A portfolio built before most pharmaceutical digital strategies existed.
Digital Generics began assembling pharmaceutical domain assets in 1998, creating a collection that is difficult to reproduce today.
A specialist portfolio centered on generic medicines and pharmaceutical terminology.
Globally recognized commercial domain names built around established pharmaceutical terms.
Many of the portfolio assets have been held since the early era of the commercial web.
Pharmaceutical companies can contact Digital Generics directly to discuss a relevant domain acquisition.
Which generic drug name should your company own?
Explore more than 240 premium pharmaceutical domain names or contact us directly about an asset that fits your portfolio.